Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/32183
Title: Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.
Authors: 
Keywords: 
Mesh: 
Issue Date: Aug-2017
Citation: J. Cancer Res. Clin. Oncol..2017 Aug;(143)8:1585-1596
Abstract: Achievement of deep molecular response with a tyrosine kinase inhibitor in patients with chronic myeloid leukemia (CML) is required to attempt discontinuation of therapy in these patients. The current subanalysis from the Evaluating Nilotinib Efficacy and Safety in Clinical Trials as First-Line Treatment (ENEST1st) study evaluated whether age has an impact on the achievement of deeper molecular responses or safety with frontline nilotinib in patients with CML.
PMID: 28364360
URI: https://hdl.handle.net/20.500.12530/32183
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. La Princesa > Artículos

Files in This Item:
File Description SizeFormat 
PMC5504128.pdf847.07 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.